Visby Medical said it plans to use the investment to scale its production capacity and expand into advanced respiratory tests and antimicrobial resistance panels, according to a June 29 news release. Founded in 2012, the company previously released a sexually transmitted disease test for women that provides results in less than 30 minutes.
“Especially during these times of market slowdown, our investors have shown significant confidence in Visby’s innovative technology and mission,” Visby Medical founder and CEO Adam de la Zerda, PhD, said in the release. “This funding will enable us to further our goal to provide the world’s first instrument-free handheld PCR platform to accurately and rapidly test for a variety of serious infections to anyone who needs it.”
The over-subscribed series E funding round was led by Lightrock and included venture capitalist John Doerr. Lightrock partner Ashish Puri said the company’s diagnostics tool has the “potential to decentralize lab testing, producing major benefits for communities around the world and opening up access to affordable healthcare results,” according to the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.